Spots Global Cancer Trial Database for Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
Official Title: Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.
Study ID: NCT01654185
Conditions
Study Description
Brief Summary: The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic breast cancer.
Detailed Description: The addition of dimethyldiguanide might increase the efficacy of AI in patients with metastatic breast cancer after the failure of the first line endocrine therapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Cancer Hospital, Shanghai, , China
Contact Details
Name: Xichun Hu, MD,PhD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
